MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Nature Reviews Drug Discovery' source. Wed, 08 Feb 2012 14:04:24 +0100 http://www.medworm.com/index.php?rid=5648106&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FK8T-oiktT8Y%2Fnrd3560-c1 Authors: Brad Spellberg, Priya Sharma & John H. Rex As summarized in a recent article (Antibacterial R&D incentives. Nature Rev. Drug Discov.10, 727–728 (2011)), numerous 'push' and 'pull' economic incentives have been proposed to rekindle the antibiotic pipeline. These have been the (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648106 Wed, 01 Feb 2012 05:00:00 +0100 5648106 http://www.medworm.com/index.php?rid=5648105&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F0PxMQdK0d3g%2Fnrd3628 Authors: Mark J. Millan, Yves Agid, Martin Brüne, Edward T. Bullmore, Cameron S. Carter, Nicola S. Clayton, Richard Connor, Sabrina Davis, Bill Deakin, Robert J. DeRubeis, Bruno Dubois, Mark A. Geyer, Guy M. Goodwin, Philip Gorwood, Thérèse M. Jay, Marian Joëls, Isabelle M. Mansuy, Andreas Meyer-Lindenberg, Declan Murphy, Edmund Rolls, Bernd Saletu, Michael Spedding, John Sweeney, Miles Whittington & Larry J. Young Studies of psychiatric disorders have traditionally focused on emotional symptoms such as depression, anxiety and hallucinations. However, poorly controlled cognitive deficits are equally prominent and severely compromise quality of life, including social and professional integration. Consequently, intensive efforts are being made to characterize the cellular (Source: Na... Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648105 Wed, 01 Feb 2012 05:00:00 +0100 5648105 http://www.medworm.com/index.php?rid=5648103&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F_HhAfmkEKkY%2Fnrd3627 Authors: Simone Fulda & Domagoj Vucic Evasion of apoptosis is one of the crucial acquired capabilities used by cancer cells to fend off anticancer therapies. Inhibitor of apoptosis (IAP) proteins exert a range of biological activities that promote cancer cell survival and proliferation. X chromosome-linked IAP is a direct inhibitor of (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648103 Wed, 01 Feb 2012 05:00:00 +0100 5648103 http://www.medworm.com/index.php?rid=5648102&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F-YQ34euN-ic%2Fnrd3672 Nature Reviews Drug Discovery 11, 108 (2012). doi:10.1038/nrd3672 Author: Charlotte Harrison Cellular metabolism has a key role in the pathogenesis of Huntington's disease (HD), which is caused by the accumulation of mutant huntingtin protein (HTT). These two studies show that sirtuin 1 (SIRT1), an NAD-dependent protein deacetylase involved in the control of cellular metabolism, has neuroprotective (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648102 Wed, 01 Feb 2012 05:00:00 +0100 5648102 http://www.medworm.com/index.php?rid=5648101&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FOrJ3_kaLzaw%2Fnrd3671 Nature Reviews Drug Discovery 11, 108 (2012). doi:10.1038/nrd3671 Author: Charlotte Harrison Cami et al. describe a computational network-based method for predicting adverse drug reactions (ADRs). They collected drug safety data from 2005 and used it to construct a network of known drug–ADR associations. This was used to train a logistic regression model to predict unknown (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648101 Wed, 01 Feb 2012 05:00:00 +0100 5648101 http://www.medworm.com/index.php?rid=5648100&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FsdDnKzDCeD4%2Fnrd3670 This study showed that blockade of TGFβ improved disease symptoms in a mouse model of cigarette smoke-induced emphysema. Administration of a TGFβ-specific neutralizing antibody prevented alveolar cell death, and improved (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648100 Wed, 01 Feb 2012 05:00:00 +0100 5648100 http://www.medworm.com/index.php?rid=5648099&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FllI5D8sKgf4%2Fnrd3664 Nature Reviews Drug Discovery 11, 108 (2012). doi:10.1038/nrd3664 Author: Darren J. Burgess Inhibiting the oncogenic kinase BCR–ABL1, which causes chronic myeloid leukaemia (CML), is a paradigm for clinically successful targeted therapy. However, drug-resistant mutations frequently emerge during clinical treatment. A new study shows that attempting to inhibit drug-resistant BCR–ABL1 mutants can result in a counterproductive activation of (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648099 Wed, 01 Feb 2012 05:00:00 +0100 5648099 http://www.medworm.com/index.php?rid=5648098&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FhiCYCUlvh7A%2Fnrd3663 Nature Reviews Drug Discovery 11, 107 (2012). doi:10.1038/nrd3663 Author: Peter Kirkpatrick The concept of drug-likeness — which is based on the observation that physicochemical properties of drugs, such as molecular mass and lipophilicity, tend to fall within a relatively narrow range of the possible values — is widely used to prioritize compounds in early-stage drug discovery. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648098 Wed, 01 Feb 2012 05:00:00 +0100 5648098 http://www.medworm.com/index.php?rid=5648094&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fq2JeowFQTT8%2Fnrd3652 Authors: Ruben A. Mesa, Uma Yasothan & Peter Kirkpatrick In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648094 Wed, 01 Feb 2012 05:00:00 +0100 5648094 http://www.medworm.com/index.php?rid=5648093&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FFupCslL3uBI%2Fnrd3624 This article discusses the drug pipeline for neuropathic pain, for which the market is forecast to grow by 50% by 2020. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648093 Wed, 01 Feb 2012 05:00:00 +0100 5648093 http://www.medworm.com/index.php?rid=5648092&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FXNrXe3Cwdtc%2Fnrd3668 Nature Reviews Drug Discovery 11, 100 (2012). doi:10.1038/nrd3668 Late last year Merck & Co. announced plans to spend US$1.5 billion to bolster research and development (R&D) in China, one of the industry's largest investments in the country to date. The firm's initial plans include, by 2014, the construction of an Asian R&D headquarters in Beijing and a doubling of their Chinese research staff count to 600 employees. Overseeing the expansion is RuiPing Dong, head of emerging markets R&D. Prior to joining Merck in 2010, Dong headed up Bristol-Myers Squibb's R&D efforts in Asia-Pacific and the emerging markets, and supervised AstraZeneca's oncology programmes. Speaking with Asher Mullard, he explains the strategy behind the Chinese R&D expansion. (So... Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648092 Wed, 01 Feb 2012 05:00:00 +0100 5648092 http://www.medworm.com/index.php?rid=5648091&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FN_LAbPt33QY%2Fnrd3667 Nature Reviews Drug Discovery 11, 98 (2012). doi:10.1038/nrd3667 Author: Charlotte Harrison Regeneron and Genentech's VEGF trap dispute settles... and continues Regeneron and Genentech have settled their patent dispute over Eylea (aflibercept) — a treatment for wet age-related macular degeneration — which was launched onto the US market in November 2011. But the biotech companies are still (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648091 Wed, 01 Feb 2012 05:00:00 +0100 5648091 http://www.medworm.com/index.php?rid=5648089&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FcPAashHGGX4%2Fnrd3655 Nature Reviews Drug Discovery 11, 96 (2012). doi:10.1038/nrd3655 Author: Sarah Crunkhorn In one of the largest preclinical-stage deals ever, Abbott has agreed to pay US$400 million upfront to Reata Pharmaceuticals as part of an agreement to jointly develop and commercialize a series of second-generation oral antioxidant inflammation modulators (AIMs) with potential applications in cardiovascular disease, neurodegenerative (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648089 Wed, 01 Feb 2012 05:00:00 +0100 5648089 http://www.medworm.com/index.php?rid=5648088&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FHTFHZMkPhh4%2Fnrd3666 Nature Reviews Drug Discovery 11, 95 (2012). doi:10.1038/nrd3666 Globalization of clinical trials plateaus?The off-shoring of clinical trials outside the United States and Europe may have hit a plateau.The lowdown: Over the past decade, drug sponsors have increasingly shifted clinical trial programmes from the United States and Europe to the rest (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648088 Wed, 01 Feb 2012 05:00:00 +0100 5648088 http://www.medworm.com/index.php?rid=5648087&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F1pvjb2f0Aso%2Fnrd3657 Nature Reviews Drug Discovery 11, 91 (2012). doi:10.1038/nrd3657 Author: Asher Mullard The US FDA approved 30 new therapeutics last year, including 11 first-in-class agents. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648087 Wed, 01 Feb 2012 05:00:00 +0100 5648087 http://www.medworm.com/index.php?rid=5648086&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FFxTLercr-6c%2Fnrd3659 Nature Reviews Drug Discovery 11, 89 (2012). doi:10.1038/nrd3659 Author: Isaac S. Kohane Genome-wide screening is anticipated to accelerate the development of personalized medicine by identifying and exploiting new associations between genomic variants and drug responses. However, this goal could be undermined if care is not taken to minimize the impact of pharmacogenomic associations that turn out to (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648086 Wed, 01 Feb 2012 05:00:00 +0100 5648086 http://www.medworm.com/index.php?rid=5648085&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F3m8iiidEDnE%2Fnrd3658 Nature Reviews Drug Discovery 11, 87 (2012). doi:10.1038/nrd3658 Recent advances in RNA biology have accelerated the progress of a new generation of molecular therapies based on RNA, with several agents now in advanced clinical trials. In our first Review, Kole and colleagues compare and contrast the mechanisms of action and effects of three (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648085 Wed, 01 Feb 2012 05:00:00 +0100 5648085 http://www.medworm.com/index.php?rid=5648108&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FTzznhInCWXw%2Fnrd3653 Nature Reviews Drug Discovery 11, 168 (2012). doi:10.1038/nrd3653 Author: Christopher D. Fjell, Jan A. Hiss, Robert E. W. Hancock & Gisbert Schneider Nature Reviews Drug Discovery11, 37–51 (2012) 10.1038/nrd3591The page numbers of reference 180 in this article are incorrect; these should be 10686–10689. This has been corrected in the online version of the article. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648108 Fri, 20 Jan 2012 05:00:00 +0100 5648108 http://www.medworm.com/index.php?rid=5648104&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FgoYLJ_0YoSA%2Fnrd3625 Authors: Ryszard Kole, Adrian R. Krainer & Sidney Altman Here, we discuss three RNA-based therapeutic technologies exploiting various oligonucleotides that bind to RNA by base pairing in a sequence-specific manner yet have different mechanisms of action and effects. RNA interference and antisense oligonucleotides downregulate gene expression by inducing enzyme-dependent degradation of targeted mRNA. Steric-blocking (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648104 Fri, 20 Jan 2012 05:00:00 +0100 5648104 http://www.medworm.com/index.php?rid=5648097&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FOWUTfMa0iFk%2Fnrd3661 Nature Reviews Drug Discovery 11, 106 (2012). doi:10.1038/nrd3661 Author: Monica Hoyos Flight The recurrence and mortality rate of patients with glioblastoma multiforme (GBM) is close to 100%. At present, therapy consists of surgical debulking of the tumour followed by radiation therapy and chemotherapy. Preclinical studies have shown that therapeutically engineered stem cells may be well suited to (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648097 Fri, 20 Jan 2012 05:00:00 +0100 5648097 http://www.medworm.com/index.php?rid=5648096&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FHOXXAx2iqcE%2Fnrd3660 Nature Reviews Drug Discovery 11, 106 (2012). doi:10.1038/nrd3660 Author: Charlotte Harrison Although preclinical studies suggest that fibroblast growth factor 21 (FGF21) might have disease-modifying properties in obesity and type 2 diabetes, recombinant FGF21 protein has poor pharmacokinetics, which precludes its clinical use. Now, writing in Science Translational Medicine, a group from Genentech describes the identification (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648096 Fri, 20 Jan 2012 05:00:00 +0100 5648096 http://www.medworm.com/index.php?rid=5648095&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FxthRGMiZxR8%2Fnrd3662 Nature Reviews Drug Discovery 11, 105 (2012). doi:10.1038/nrd3662 Author: Sarah Crunkhorn The maintenance of protein homeostasis (proteostasis) is vital for cell function and involves a tightly regulated network of pathways controlling the synthesis, folding, transport and degradation of proteins. Loss of proteostatic control can lead to the accumulation and aggregation of misfolded proteins — features that (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648095 Fri, 20 Jan 2012 05:00:00 +0100 5648095 http://www.medworm.com/index.php?rid=5648090&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FSYA8GoXAgWQ%2Fnrd3656 Nature Reviews Drug Discovery 11, 96 (2012). doi:10.1038/nrd3656 Author: Charlotte Harrison Preliminary clinical trial data recently presented at the American Society of Hematology meeting showed that the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 was effective in treating in several types of B cell lymphoma. Furthermore, PCI-32765 is at the centre of a deal — worth up (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648090 Fri, 20 Jan 2012 05:00:00 +0100 5648090 http://www.medworm.com/index.php?rid=5560351&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FLgnQZNRJAJQ%2Fnrd3615 Authors: Rithwik Ramachandran, Farshid Noorbakhsh, Kathryn DeFea & Morley D. Hollenberg Proteinase-activated receptors (PARs), a family of four seven-transmembrane G protein-coupled receptors, act as targets for signalling by various proteolytic enzymes. PARs are characterized by a unique activation mechanism involving the proteolytic unmasking of a tethered ligand that stimulates the receptor. Given the emerging roles of (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560351 Tue, 03 Jan 2012 05:00:00 +0100 5560351 http://www.medworm.com/index.php?rid=5560350&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FVc6UMe9Rzxc%2Fnrd3620 Authors: Daniel A. Bachovchin & Benjamin F. Cravatt Serine hydrolases perform crucial roles in many biological processes, and several of these enzymes are targets of approved drugs for indications such as type 2 diabetes, Alzheimer's disease and infectious diseases. Despite this, most of the human serine hydrolases (of which there are more than (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560350 Tue, 03 Jan 2012 05:00:00 +0100 5560350 http://www.medworm.com/index.php?rid=5560347&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FhSsf4FOycEY%2Fnrd3635 Nature Reviews Drug Discovery 11, 24 (2012). doi:10.1038/nrd3635 Author: Peter Kirkpatrick Most existing and investigational drugs for malaria are targeted at the stages of the Plasmodium spp. parasite life cycle in red blood cells, which underlie the disease manifestations. Targeting the earlier-stage exo-erythocytic forms, which multiply in the host liver following infection before emerging into (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560347 Tue, 03 Jan 2012 05:00:00 +0100 5560347 http://www.medworm.com/index.php?rid=5560346&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FqWKj5ajl9PI%2Fnrd3636 Nature Reviews Drug Discovery 11, 23 (2012). doi:10.1038/nrd3636 Author: Alexandra Flemming The ubiquitin–proteasome system is a crucial regulator of growth and apoptosis. The first proteasome-targeted drug, bortezomib, was approved in 2003 for the treatment of multiple myeloma and validated the 20S proteolytic subunit of the proteasome as an anticancer target. Now, reporting in Nature Medicine, (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560346 Tue, 03 Jan 2012 05:00:00 +0100 5560346 http://www.medworm.com/index.php?rid=5560345&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fm-h8_V7hRjE%2Fnrd3638 Nature Reviews Drug Discovery 11, 22 (2012). doi:10.1038/nrd3638 Author: Katrin Legg Activation of TGR5, a G protein-coupled receptor for bile acids, has been linked to both improved glycaemic control and enhanced energy expenditure. Now, the discovery by Pols and colleagues, reported in Cell Metabolism, that activation of TGR5 also protects against the development of atherosclerosis (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560345 Tue, 03 Jan 2012 05:00:00 +0100 5560345 http://www.medworm.com/index.php?rid=5560343&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FdYt_PIvViPw%2Fnrd3647 Nature Reviews Drug Discovery 11, 21 (2012). doi:10.1038/nrd3647 Author: Charlotte Harrison Most small-molecule kinase inhibitors interact with multiple members of the protein kinase family; achieving selective inhibition of specific protein kinases is challenging. These two papers describe studies of kinase inhibitor selectivity. Anastassiadis et al. profiled the activity of 178 kinase inhibitors against a panel (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560343 Tue, 03 Jan 2012 05:00:00 +0100 5560343 http://www.medworm.com/index.php?rid=5560342&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FnE4vDRZTZ24%2Fnrd3646 Nature Reviews Drug Discovery 11, 21 (2012). doi:10.1038/nrd3646 Author: Charlotte Harrison Hack et al. described a novel approach for enhancing the diversity of chemical libraries. Compounds for potential acquisition (filtered to remove non-drug-like compounds) were added to those in a corporate library, and the overall group was organized into clusters using an algorithm that emphasized (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560342 Tue, 03 Jan 2012 05:00:00 +0100 5560342 http://www.medworm.com/index.php?rid=5560341&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FgwrDju1ge0U%2Fnrd3645 Nature Reviews Drug Discovery 11, 21 (2012). doi:10.1038/nrd3645 Author: Charlotte Harrison The β-secretase-mediated generation of amyloid-β peptide (Aβ) is involved in the pathogenesis of Alzheimer's disease. This paper describes the characterization of the first orally available non-peptidic β-secretase inhibitor, LY2811376. The β-secretase 1 (BACE1) inhibitor, which was identified by fragment-based screening, lowered Aβ levels in a (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560341 Tue, 03 Jan 2012 05:00:00 +0100 5560341 http://www.medworm.com/index.php?rid=5560339&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F7xVFfH4v_nc%2Fnrd3629 Authors: Anas Younes, Uma Yasothan & Peter Kirkpatrick In August 2011 brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody–drug conjugate, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with Hodgkin's lymphoma and patients with systemic anaplastic large cell lymphoma (ALCL). (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560339 Tue, 03 Jan 2012 05:00:00 +0100 5560339 http://www.medworm.com/index.php?rid=5560338&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FjX_7zleGgjU%2Fnrd3630 Nature Reviews Drug Discovery 11, 17 (2012). doi:10.1038/nrd3630 Author: John Arrowsmith Data on indicators such as the number and success rate of research and development projects illustrate trends in the pharmaceutical industry over the past decade. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560338 Tue, 03 Jan 2012 05:00:00 +0100 5560338 http://www.medworm.com/index.php?rid=5560337&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F5_t8-t7xtTY%2Fnrd3640 Nature Reviews Drug Discovery 11, 14 (2012). doi:10.1038/nrd3640 Mark Fishman started heading up research & development (R&D) at Novartis, as President of the Novartis Institutes for BioMedical Research (NIBR), 10 years ago. Prior to joining the drug firm in 2002, Fishman worked as a cardiologist, with a research focus on using zebrafish as a model for cardiovascular disease. He has since, however, helped to usher in a focus on rare diseases and pathway-based research at Novartis. Speaking with Asher Mullard, he looked back on a decade of R&D at Novartis and discussed how R&D trends could evolve in the next 10 years. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560337 Tue, 03 Jan 2012 05:00:00 +0100 5560337 http://www.medworm.com/index.php?rid=5560336&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FEPfZNZKCMVE%2Fnrd3641 Nature Reviews Drug Discovery 11, 12 (2012). doi:10.1038/nrd3641 Author: Charlotte Harrison Key patent-related events of the past 10 yearsTo celebrate the 10-year anniversary of Nature Reviews Drug Discovery, we asked our patent advisors for their views on the most noteworthy patent-related events of the past decade.JapanAccording to John A. Tessensohn, an attorney (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560336 Tue, 03 Jan 2012 05:00:00 +0100 5560336 http://www.medworm.com/index.php?rid=5560335&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FgvFPi6pcLok%2Fnrd3633 Nature Reviews Drug Discovery 11, 11 (2012). doi:10.1038/nrd3633 Author: Sarah Crunkhorn Preliminary Phase II trial results for REGN727 — a human proprotein convertase subtilisin/kexin type 9 (PCSK9)-specific monoclonal antibody co-developed by Regeneron and Sanofi — indicate that it effectively and safely reduces levels of low-density lipoprotein-cholesterol (LDL-C) in patients with hypercholesterolaemia undergoing statin therapy.Statins are (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560335 Tue, 03 Jan 2012 05:00:00 +0100 5560335 http://www.medworm.com/index.php?rid=5560334&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FKDbW93tn8rk%2Fnrd3632 Nature Reviews Drug Discovery 11, 10 (2012). doi:10.1038/nrd3632 Author: Edny Inui Important catalysts for the first quarter of 2012 include approval decisions on vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC), and on peginesatide for anaemia associated with chronic kidney disease (CKD). Top-line Phase III data are also expected for tivozanib for (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560334 Tue, 03 Jan 2012 05:00:00 +0100 5560334 http://www.medworm.com/index.php?rid=5560333&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FuChXk6FnpOE%2Fnrd3631 Nature Reviews Drug Discovery 11, 10 (2012). doi:10.1038/nrd3631 Author: Monica Hoyos Flight Biogen Idec and Portola Pharmaceuticals have entered into a licensing agreement to develop and commercialize PRT062607, a novel oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of rheumatoid arthritis as well as other autoimmune and inflammatory diseases.Under the terms of the agreement, Biogen (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560333 Tue, 03 Jan 2012 05:00:00 +0100 5560333 http://www.medworm.com/index.php?rid=5560332&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FCagYWsC8MeE%2Fnrd3644 Nature Reviews Drug Discovery 11, 9 (2012). doi:10.1038/nrd3644 Falling R&D returns?The internal rate of return for R&D has fallen on average from 11.8% in 2010 to 8.4% in 2011, finds a joint analysis by Deloitte and Thomson Reuters.The lowdown: An annual review by Deloitte and Thomson Reuters set out (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560332 Tue, 03 Jan 2012 05:00:00 +0100 5560332 http://www.medworm.com/index.php?rid=5560331&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FMImDrMxhwrQ%2Fnrd3643 Nature Reviews Drug Discovery 11, 6 (2012). doi:10.1038/nrd3643 Author: Asher Mullard Last year saw an upturn in new drug approvals, the end of patent protection for the world's top-selling drug, continued regulatory negotiations and more. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560331 Tue, 03 Jan 2012 05:00:00 +0100 5560331 http://www.medworm.com/index.php?rid=5560330&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F6pk_KKbG9nQ%2Fnrd3642 Nature Reviews Drug Discovery 11, 5 (2012). doi:10.1038/nrd3642 Author: Simon Frantz WIPO Re:Search aims to encourage drug discovery for neglected diseases by broadening the scope of the assets members are willing to share. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560330 Tue, 03 Jan 2012 05:00:00 +0100 5560330 http://www.medworm.com/index.php?rid=5560329&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FwsepINZU1Bk%2Fnrd3648 Nature Reviews Drug Discovery 11, 3 (2012). doi:10.1038/nrd3648 Nature Reviews Drug Discovery marks its tenth anniversary this month, providing an opportunity to reflect on the evolution of the landscape of drug research and development (R&D). (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560329 Tue, 03 Jan 2012 05:00:00 +0100 5560329 http://www.medworm.com/index.php?rid=5560328&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FBv1fDNepIeY%2Fnrd3639 Nature Reviews Drug Discovery 11, 1 (2012). doi:10.1038/nrd3639 This month we are delighted to be celebrating 10 years of Nature Reviews Drug Discovery (see the editorial on page 3). Reflecting our continuing aim to feature articles across the broad spectrum of areas relevant to drug discovery and development, our Review articles (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560328 Tue, 03 Jan 2012 05:00:00 +0100 5560328 http://www.medworm.com/index.php?rid=5648107&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Ftz9psYU03Qk%2Fnrd3650 Nature Reviews Drug Discovery 11, 168 (2012). doi:10.1038/nrd3650 Author: Alisa Opar Nature Reviews Drug Discovery10, 887–888 (2011) The spelling of Stephen Hoffman's name has been corrected online, as has his affiliation. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5648107 Fri, 23 Dec 2011 05:00:00 +0100 5648107 http://www.medworm.com/index.php?rid=5560349&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FVzVLO0c9WJo%2Fnrd3591 Authors: Christopher D. Fjell, Jan A. Hiss, Robert E. W. Hancock & Gisbert Schneider Multidrug-resistant bacteria are a severe threat to public health. Conventional antibiotics are becoming increasingly ineffective as a result of resistance, and it is imperative to find new antibacterial strategies. Natural antimicrobials, known as host defence peptides or antimicrobial peptides, defend host organisms against microbes but (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560349 Fri, 16 Dec 2011 05:00:00 +0100 5560349 http://www.medworm.com/index.php?rid=5560348&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FDIRc35Ab4Hc%2Fnrd3404 Authors: Yves Pommier & Christophe Marchand Interfacial inhibitors belong to a broad class of natural products and synthetic drugs that are commonly used to treat cancers as well as bacterial and HIV infections. They bind selectively to interfaces as macromolecular machines assemble and are set in motion. The bound drugs transiently (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560348 Fri, 16 Dec 2011 05:00:00 +0100 5560348 http://www.medworm.com/index.php?rid=5560344&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F0zhcnr_rVOs%2Fnrd3634 Nature Reviews Drug Discovery 11, 22 (2012). doi:10.1038/nrd3634 Author: Sarah Crunkhorn Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease characterized by degeneration of the upper and lower motor neurons, causing muscle weakness and atrophy throughout the body. The only approved disease-modifying treatment for ALS is riluzole (which has effects on both the excitatory amino (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560344 Fri, 16 Dec 2011 05:00:00 +0100 5560344 http://www.medworm.com/index.php?rid=5560340&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F8WKzY3qNZkI%2Fnrd3637 Nature Reviews Drug Discovery 11, 21 (2012). doi:10.1038/nrd3637 Author: Monica Hoyos Flight Carrier proteins coupled to polysaccharides that are extracted from bacterial cell walls are used as vaccines to prevent many infectious diseases such as pneumonia and meningitis. These glycoconjugate vaccines elicit a T cell response that boosts the production of high-affinity antibodies against the polysaccharide by (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5560340 Fri, 16 Dec 2011 05:00:00 +0100 5560340 http://www.medworm.com/index.php?rid=5457940&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fj44gfy9Y-dA%2Fnrd3599 Authors: Joon-Il Jun & Lester F. Lau Members of the CCN family of matricellular proteins are crucial for embryonic development and have important roles in inflammation, wound healing and injury repair in adulthood. Deregulation of CCN protein expression or activities contributes to the pathobiology of various diseases — many of which may (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457940 Thu, 01 Dec 2011 05:00:00 +0100 5457940 http://www.medworm.com/index.php?rid=5457939&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FHamQMV_Nyws%2Fnrd3453 Authors: Daniel W. Neef, Alex M. Jaeger & Dennis J. Thiele Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and prion-based neurodegeneration are associated with the accumulation of misfolded proteins, resulting in neuronal dysfunction and cell death. However, current treatments for these diseases predominantly address disease symptoms, rather than the underlying (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457939 Thu, 01 Dec 2011 05:00:00 +0100 5457939 http://www.medworm.com/index.php?rid=5457936&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FG6W5AZbMlXY%2Fnrd3619 This study used phosphorodiamidate morpholino oligomers to redirect STAT3 alternative splicing from STAT3α (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457936 Thu, 01 Dec 2011 05:00:00 +0100 5457936 http://www.medworm.com/index.php?rid=5457935&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FksKSLszvx58%2Fnrd3618 Nature Reviews Drug Discovery 10, 902 (2011). doi:10.1038/nrd3618 Author: Charlotte Harrison Protein tyrosine phosphatase 1B (PTP1B) is an established target for diabetes and obesity but identifying drug-like PTP1B inhibitors has proved challenging. Haque et al. generated single-chain variable fragments of antibodies that stabilized the oxidized form of PTP1B and so inhibited its phosphatase function. Intracellular (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457935 Thu, 01 Dec 2011 05:00:00 +0100 5457935 http://www.medworm.com/index.php?rid=5457934&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FQXyYSJQDm-Y%2Fnrd3617 Nature Reviews Drug Discovery 10, 902 (2011). doi:10.1038/nrd3617 Author: Charlotte Harrison Medulloblastomas are the most common malignant brain tumours in children. This paper showed that a large proportion of primary medulloblastomas are infected with human cytomegalovirus (HCMV), and the virus directly modulates the expression of cyclooxygenase 2 (COX2) and levels of prostaglandin E2 (PGE (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457934 Thu, 01 Dec 2011 05:00:00 +0100 5457934 http://www.medworm.com/index.php?rid=5457933&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fx1zZftSUKWU%2Fnrd3616 Nature Reviews Drug Discovery 10, 902 (2011). doi:10.1038/nrd3616 Author: Charlotte Harrison Park et al. have discovered a new pathway for the biosynthesis of the widely used aminoglycoside antibiotic kanamycin. This pathway — which consists of two branches — contains previously unknown intermediates that are subject to further modification and lead to the independent production of (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457933 Thu, 01 Dec 2011 05:00:00 +0100 5457933 http://www.medworm.com/index.php?rid=5457932&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FIel5L6Vo1mU%2Fnrd3604 Nature Reviews Drug Discovery 10, 902 (2011). doi:10.1038/nrd3604 Author: Monica Hoyos Flight Stents are implanted to dilate arteries narrowed by atherosclerotic plaques and to revascularize coronary arteries following myocardial infarction. However, in up to 20% of patients the regrowth of cells in the inner vessel wall (neointima) or incomplete healing of the endothelial cell lining in the (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457932 Thu, 01 Dec 2011 05:00:00 +0100 5457932 http://www.medworm.com/index.php?rid=5457930&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FU0cX-tmk_ok%2Fnrd3608 Nature Reviews Drug Discovery 10, 900 (2011). doi:10.1038/nrd3608 Author: Alexandra Flemming Spinal muscular atrophy (SMA), a degenerative neuromuscular disease that is caused by a genetic defect in the survival of motor neuron 1 (SMN1) gene, is a leading cause of infant mortality. There is no effective treatment at present. Reporting in Nature, Krainer (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457930 Thu, 01 Dec 2011 05:00:00 +0100 5457930 http://www.medworm.com/index.php?rid=5457927&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FtcTRyVR2ad4%2Fnrd3600 Authors: Alice T. Shaw, Uma Yasothan & Peter Kirkpatrick In August 2011 crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-positive, as detected by an FDA-approved test. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457927 Thu, 01 Dec 2011 05:00:00 +0100 5457927 http://www.medworm.com/index.php?rid=5457926&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F5kdJ_T1HqD0%2Fnrd3603 Authors: Alex Chiang & Ryan P. Million Emerging insights into the basic biology of cancer have led to the development of novel, tailored treatments for patients based on existing specific genetic profiles and other biomarkers. Several of these, such as Herceptin and Gleevec, have shown considerable commercial success, with worldwide sales of (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457926 Thu, 01 Dec 2011 05:00:00 +0100 5457926 http://www.medworm.com/index.php?rid=5457925&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FDCw4ePICAlk%2Fnrd3613 Nature Reviews Drug Discovery 10, 894 (2011). doi:10.1038/nrd3613 Harvard Medical School has launched the Initiative in Systems Pharmacology (ISP), a new effort aimed at using systems biology approaches to help address industry's pipeline problems. Despite the applied end goal, the programme's focus will be on developing the basic science of understanding how drugs interact with and perturb complex systems, says Marc Kirschner, Chairman of Harvard Medical School's Department of Systems Biology and sponsor of the initiative. Speaking with Asher Mullard, Kirschner outlined his vision for the ISP. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457925 Thu, 01 Dec 2011 05:00:00 +0100 5457925 http://www.medworm.com/index.php?rid=5457923&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FWc-Iibm96GU%2Fnrd3623 Nature Reviews Drug Discovery 10, 891 (2011). doi:10.1038/nrd3623 The current standard of care (SOC) for hepatitis C virus (HCV) infection involves treatment with ribavirin and pegylated interferon (PEG-IFN). This stimulates the immune system rather than targeting the virus directly, and is associated with severe side effects. Earlier this year, the first two direct-acting (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457923 Thu, 01 Dec 2011 05:00:00 +0100 5457923 http://www.medworm.com/index.php?rid=5457922&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fup3BRayebPk%2Fnrd3622 Nature Reviews Drug Discovery 10, 890 (2011). doi:10.1038/nrd3622 GlycoMimetics has granted Pfizer exclusive worldwide rights to develop and commercialize GMI-1070, a rationally designed glycomimetic inhibitor of E-, L- and P-selectin, for vaso-occlusive crisis associated with sickle cell disease (SCD). Under the terms of the agreement, which could be worth up to US$340 million (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457922 Thu, 01 Dec 2011 05:00:00 +0100 5457922 http://www.medworm.com/index.php?rid=5457921&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FGl4g5JdgYgM%2Fnrd3621 Nature Reviews Drug Discovery 10, 890 (2011). doi:10.1038/nrd3621 Les Laboratoires Servier and MiRagen Therapeutics have agreed to jointly research, develop and commercialize three preclinical-stage oligonucleotide microRNA inhibitors — targeting microRNA-208 (miR208), miR-15/195 and an unidentified miRNA — for the treatment of cardiovascular disease. MiRagen will receive an upfront fee of US$45 million, with (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457921 Thu, 01 Dec 2011 05:00:00 +0100 5457921 http://www.medworm.com/index.php?rid=5457920&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FefdegxpiuhQ%2Fnrd3609 Nature Reviews Drug Discovery 10, 889 (2011). doi:10.1038/nrd3609 End of the Lipitor eraPfizer's atorvastatin (Lipitor) — which cumulatively grossed over US$130 billion in sales since its approval in 1996 — came off patent on 30 November.The lowdown: Atorvastatin was first synthesized in 1985 by Bruce Roth, who at the time (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457920 Thu, 01 Dec 2011 05:00:00 +0100 5457920 http://www.medworm.com/index.php?rid=5457919&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FcX7WuYHnBTc%2Fnrd3611 Nature Reviews Drug Discovery 10, 887 (2011). doi:10.1038/nrd3611 Author: Alisa Opar The long development of RTS,S, the leading malaria vaccine candidate, has yielded preliminary positive Phase III results, and laid a path for future success. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457919 Thu, 01 Dec 2011 05:00:00 +0100 5457919 http://www.medworm.com/index.php?rid=5457918&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FqVFXRJWRlDQ%2Fnrd3610 Nature Reviews Drug Discovery 10, 885 (2011). doi:10.1038/nrd3610 Author: Asher Mullard With six immunomodulatory agents in late-stage development for relapsing–remitting multiple sclerosis, this area of the therapeutic space has become highly competitive. Could remyelination therapies that provide neuroprotection be the next frontier? (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457918 Thu, 01 Dec 2011 05:00:00 +0100 5457918 http://www.medworm.com/index.php?rid=5457917&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FVeSc1zEMUH0%2Fnrd3602 Nature Reviews Drug Discovery 10, 883 (2011). doi:10.1038/nrd3602 Developing collaborative approaches to provide greater confidence in the validity of novel drug targets may have a key role in reducing clinical attrition in the long term. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457917 Thu, 01 Dec 2011 05:00:00 +0100 5457917 http://www.medworm.com/index.php?rid=5457916&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FB8nChI0OVv0%2Fnrd3601 Nature Reviews Drug Discovery 10, 881 (2011). doi:10.1038/nrd3601 The generation of induced pluripotent stem cells (iPSCs) from human somatic cells has provided a new platform for studying disease pathogenesis and for cell-based phenotypic screening to identify novel therapies. In their Review, Daley and colleagues discuss key issues and recent advances associated with the (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457916 Thu, 01 Dec 2011 05:00:00 +0100 5457916 http://www.medworm.com/index.php?rid=5457937&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F6sIlMVYdXy4%2Fnrd3576 Authors: Otilia Postea & Martin Biel Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels have a key role in the control of heart rate and neuronal excitability. Ivabradine is the first compound acting on HCN channels to be clinically approved for the treatment of angina pectoris. HCN channels may offer excellent opportunities for the (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457937 Fri, 18 Nov 2011 05:00:00 +0100 5457937 http://www.medworm.com/index.php?rid=5457931&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F-dyedTmYpns%2Fnrd3607 Nature Reviews Drug Discovery 10, 901 (2011). doi:10.1038/nrd3607 Author: Katrin Legg The discovery in the nervous system of an alternative route for arachidonic acid (AA) production — from which cyclooxygenases (COXs) synthesize neuroinflammatory prostaglandins — might offer a safer way of suppressing the inflammation that is characteristic of neurodegenerative disorders such as Parkinson's disease. Phospholipase A2 (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457931 Fri, 18 Nov 2011 05:00:00 +0100 5457931 http://www.medworm.com/index.php?rid=5457929&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F-7eptRZLg_A%2Fnrd3606 Nature Reviews Drug Discovery 10, 900 (2011). doi:10.1038/nrd3606 Author: Charlotte Harrison Emerging evidence suggests that the development of chronic pain involves epigenetic modulation of gene expression, but it is unknown how this mechanism operates and which target genes are involved. Now, writing in Nature Medicine, Zhang et al. show that persistent pain suppresses transcription (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457929 Fri, 18 Nov 2011 05:00:00 +0100 5457929 http://www.medworm.com/index.php?rid=5457928&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FoE6fWeB1JgU%2Fnrd3605 Nature Reviews Drug Discovery 10, 899 (2011). doi:10.1038/nrd3605 Author: Sarah Crunkhorn The development of novel cardiovascular disease therapies that harness the atheroprotective functions of high-density lipoprotein (HDL) is an area of intense investigation. However, achieving safe and effective HDL-targeted agents has so far proved challenging. Now, writing in Nature, Rayner and colleagues show that inhibiting (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457928 Fri, 18 Nov 2011 05:00:00 +0100 5457928 http://www.medworm.com/index.php?rid=5457938&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fmv8QmkoMCMQ%2Fnrd3577 Authors: Marica Grskovic, Ashkan Javaherian, Berta Strulovici & George Q. Daley The ability to generate induced pluripotent stem cells (iPSCs) from patients, and an increasingly refined capacity to differentiate these iPSCs into disease-relevant cell types, promises a new paradigm in drug development — one that positions human disease pathophysiology at the core of preclinical drug discovery. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457938 Fri, 11 Nov 2011 05:00:00 +0100 5457938 http://www.medworm.com/index.php?rid=5457924&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FeR3mK0kGisA%2Fnrd3612 Nature Reviews Drug Discovery 10, 892 (2011). doi:10.1038/nrd3612 Author: Charlotte Harrison The Court of Justice of the European Union (CJEU) has prohibited the patenting of stem cells that are derived from the destruction of human embryos. Although the decision — which applies to all countries within the EU and cannot be appealed — has raised concerns (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457924 Fri, 11 Nov 2011 05:00:00 +0100 5457924 http://www.medworm.com/index.php?rid=5457942&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FWnQ39wiIPSQ%2Fnrd3614 Nature Reviews Drug Discovery 10, 963 (2011). doi:10.1038/nrd3614 Author: Mark E. Lobatto, Valentin Fuster, Zahi A. Fayad & Willem J. M. Mulder Nature Reviews Drug Discovery10, 835–852 (2011)| 10.1038/nrd3578The following sentence was inadvertently duplicated on page 835: Subsequently, several other nanomedicinal therapeutics have been approved for clinical use, including an albumin-bound nanoparticle delivering paclitaxel for the treatment of breast (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457942 Mon, 31 Oct 2011 04:00:00 +0100 5457942 http://www.medworm.com/index.php?rid=5457941&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fv0b5QWzQl0Y%2Fnrd2961-c1 Nature Reviews Drug Discovery 10, 963 (2011). doi:10.1038/nrd2961-c1 Author: Raymond A. Firestone A recent article (Lessons from 60 years of pharmaceutical innovation. Nature Rev. Drug Discov.8, 959–968 (2009)) presents a corporate perspective on the reasons why the annual output of new drugs during the past few decades has (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5457941 Mon, 31 Oct 2011 04:00:00 +0100 5457941 http://www.medworm.com/index.php?rid=5387182&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FlE-k9RdPdrU%2Fnrd3531 Authors: Don Benjamin, Marco Colombi, Christoph Moroni & Michael N. Hall Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metabolism in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders. Rapamycin is an allosteric inhibitor of mTOR, and was approved (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387182 Mon, 31 Oct 2011 04:00:00 +0100 5387182 http://www.medworm.com/index.php?rid=5387179&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FNbLrSS5BXNM%2Fnrd3557 Authors: Mark R. Trusheim, Breon Burgess, Sean Xinghua Hu, Theresa Long, Steven D. Averbuch, Aiden A. Flynn, Alfons Lieftucht, Abhijit Mazumder, Judy Milloy, Peter M. Shaw, David Sw., Jian Wang, Ernst R. Berndt, Federico Goodsaid & Michael C. Palmer Co-developing a drug with a diagnostic to create a stratified medicine — a therapy that is targeted to a specific patient population on the basis of a clinical characteristic such as a biomarker that predicts treatment response — presents challenges for product developers, regulators, payers (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387179 Mon, 31 Oct 2011 04:00:00 +0100 5387179 http://www.medworm.com/index.php?rid=5387178&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FP_rKzTRvLKk%2Fnrd3598 Nature Reviews Drug Discovery 10, 816 (2011). doi:10.1038/nrd3598 Author: Charlotte Harrison Two papers now suggest potential new lead compounds and adjuvant therapies for the treatment and management of brain tumours. Buckingham et al. investigated the aetiology of epileptic seizures caused by the presence of primary brain tumours. Brain slices from a mouse model of tumour-induced (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387178 Mon, 31 Oct 2011 04:00:00 +0100 5387178 http://www.medworm.com/index.php?rid=5387177&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FJrUjv9zqR1M%2Fnrd3597 This study compared virtual screens against a homology model of a G protein-coupled receptor and the experimentally determined crystal structure. Following determination of the crystal structure of the dopamine D3 receptor, but before the information was publicly available, the scientific community was asked to predict (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387177 Mon, 31 Oct 2011 04:00:00 +0100 5387177 http://www.medworm.com/index.php?rid=5387176&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FXPSX2DTfINY%2Fnrd3596 Nature Reviews Drug Discovery 10, 816 (2011). doi:10.1038/nrd3596 Author: Charlotte Harrison Zasloff et al. showed that squalamine, a compound first isolated from the dogfish shark and known to have antimicrobial properties, also has broad-spectrum antiviral activity against human pathogens. In vitro the compound was effective against dengue virus and hepatitis, and in vivo (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387176 Mon, 31 Oct 2011 04:00:00 +0100 5387176 http://www.medworm.com/index.php?rid=5387174&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FrH69FOKXaMU%2Fnrd3590 Nature Reviews Drug Discovery 10, 815 (2011). doi:10.1038/nrd3590 Author: Olive Leavy Inflammatory monocytes are rapidly recruited to sites of inflammation, but their excessive and/or prolonged recruitment hinders the resolution of inflammation and is a hallmark of numerous diseases. Therefore, targeting these cells could be of therapeutic value. Reporting in Nature Biotechnology, Leuschner et al. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387174 Mon, 31 Oct 2011 04:00:00 +0100 5387174 http://www.medworm.com/index.php?rid=5387173&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FTbQQCE8tLtk%2Fnrd3589 Nature Reviews Drug Discovery 10, 814 (2011). doi:10.1038/nrd3589 Author: Alexandra Flemming One of the biggest challenges for systemic anticancer treatment is to achieve sufficiently high local concentrations of the drug in the tumours, while sparing healthy tissues. Reporting in Nature, Breitbach et al. demonstrate how this problem can be addressed with a tumour-homing poxvirus (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387173 Mon, 31 Oct 2011 04:00:00 +0100 5387173 http://www.medworm.com/index.php?rid=5387171&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F3gsWNir3GXY%2Fnrd3588 Nature Reviews Drug Discovery 10, 813 (2011). doi:10.1038/nrd3588 Author: Charlotte Harrison The only vaccine against Mycobacterium tuberculosis, the attenuated Mycobacterium bovis strain bacille Calmette–Guérin (BCG), has variable efficacy and generates only partial immunity against M. tuberculosis. A possible new vaccine strategy that provides highly protective bactericidal immunity against M. tuberculosis in mice (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387171 Mon, 31 Oct 2011 04:00:00 +0100 5387171 http://www.medworm.com/index.php?rid=5387170&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FiiZ88GuCIVs%2Fnrd3579 Authors: Keith. T Flaherty, Uma Yasothan & Peter Kirkpatrick In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387170 Mon, 31 Oct 2011 04:00:00 +0100 5387170 http://www.medworm.com/index.php?rid=5387169&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FsovkOOcdQ-Q%2Fnrd3585 Nature Reviews Drug Discovery 10, 809 (2011). doi:10.1038/nrd3585 Author: Daniel Chancellor Depression is a mood disorder with a multitude of symptoms, including lowered mood, fatigue and disturbed sleep, anhedonia, low self-esteem and self-confidence, loss of appetite, and a low libido. The most common type is major depressive disorder (MDD), with dysthymia and bipolar disorder also being (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387169 Mon, 31 Oct 2011 04:00:00 +0100 5387169 http://www.medworm.com/index.php?rid=5387168&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FFzFJgUiqya8%2Fnrd3584 Nature Reviews Drug Discovery 10, 806 (2011). doi:10.1038/nrd3584 After 16 years heading up research and development at Dendreon, David Urdal is due to step down from the company at the end of this year. During his tenure he oversaw the tumultuous development and approval of the first active cancer immunotherapy — sipuleucel-T (Provenge) — for metastatic prostate cancer, which finally made it to market in 2010. Before joining Dendreon, Urdal spent 13 years at Immunex helping, among other things, to launch the first therapeutic fusion protein, etanercept (Enbrel). As he prepares to pack up his office after three decades in industry, he spoke with Asher Mullard about his latest success and the changing biotechnology sector. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387168 Mon, 31 Oct 2011 04:00:00 +0100 5387168 http://www.medworm.com/index.php?rid=5387167&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FlhUJH2llssA%2Fnrd3583 Nature Reviews Drug Discovery 10, 804 (2011). doi:10.1038/nrd3583 Isis lawsuit threatens Santaris's antisense deals and questions research exemptionAntisense technology company Isis Pharmaceuticals is suing rival Santaris Pharma, alleging that Santaris is illegally generating millions of dollars in revenue by selling technology that is covered by Isis's patents.Both Isis and Santaris focus (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387167 Mon, 31 Oct 2011 04:00:00 +0100 5387167 http://www.medworm.com/index.php?rid=5387164&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FhogHP2OMNQM%2Fnrd3582 Nature Reviews Drug Discovery 10, 801 (2011). doi:10.1038/nrd3582 Biotech funding in Europe on the rise?Venture capitalists are increasingly considering investing in European biotech firms over US-based firms, suggests an NVCA survey.The lowdown: The National Venture Capital Association (NVCA) surveyed over 150 venture capital firms — which put over US$10 (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387164 Mon, 31 Oct 2011 04:00:00 +0100 5387164 http://www.medworm.com/index.php?rid=5387163&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F4GlveJXr8cY%2Fnrd3581 Nature Reviews Drug Discovery 10, 798 (2011). doi:10.1038/nrd3581 Author: David Holmes Promising Phase II data and a flurry of deal-making indicate that bispecific platform technologies are about to take antibodies to the next level. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387163 Mon, 31 Oct 2011 04:00:00 +0100 5387163 http://www.medworm.com/index.php?rid=5387162&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FrUpkIum-b38%2Fnrd3580 Nature Reviews Drug Discovery 10, 797 (2011). doi:10.1038/nrd3580 Author: Asher Mullard An eventful year — including panel meetings, approvals and a refusal to file a new drug application — has sharpened the focus around the FDA's requirements for accelerated approval of anticancer drugs. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387162 Mon, 31 Oct 2011 04:00:00 +0100 5387162 http://www.medworm.com/index.php?rid=5387161&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FfP0jb-DXmWo%2Fnrd3595 Authors: Edward D. Bashaw, Shiew-Mei Huang, Timothy R. Coté, Anne R. Pariser, Christine E. Garnett, Gilbert Burckart, Lei Zhang, Angela Y. Men, Christine D. Le, Rosane Charlab, Jogaro V. Gobburu & Lawrence J. Lesko A recent US Food and Drug Administration (FDA) advisory committee meeting highlighted the potential of clinical pharmacology to overcome challenges in orphan drug development. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387161 Mon, 31 Oct 2011 04:00:00 +0100 5387161 http://www.medworm.com/index.php?rid=5387160&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FSSCjFlitPlU%2Fnrd3592 Nature Reviews Drug Discovery 10, 793 (2011). doi:10.1038/nrd3592 Using biomarkers to identify subsets of patients who are likely to benefit from a given therapy has the potential to substantially improve patient care and reduce the size, cost and failure rates of clinical trials. However, coordinating the co-development of a drug with a diagnostic (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387160 Mon, 31 Oct 2011 04:00:00 +0100 5387160 http://www.medworm.com/index.php?rid=5387181&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FiXV7bd5ABxE%2Fnrd3556 Authors: Dagmar E. Ehrnhoefer, Bibiana K. Y. Wong & Michael R. Hayden Neurodegenerative diseases, exemplified by Alzheimer's disease and Huntington's disease, are characterized by progressive neuropsychiatric dysfunction and loss of specific neuronal subtypes. Although there are differences in the exact sites of pathology, and the clinical profiles of these two conditions only partially overlap, considerable similarities in (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387181 Fri, 21 Oct 2011 04:00:00 +0100 5387181 http://www.medworm.com/index.php?rid=5387180&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fz-Fsxzb3-1k%2Fnrd3578 Authors: Mark E. Lobatto, Valentin Fuster, Zahi A. Fayad & Willem J. M. Mulder The use of nanotechnology for medical purposes — nanomedicine — has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387180 Fri, 21 Oct 2011 04:00:00 +0100 5387180 http://www.medworm.com/index.php?rid=5387175&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F38IRt_7xvI0%2Fnrd3586 Nature Reviews Drug Discovery 10, 816 (2011). doi:10.1038/nrd3586 Author: Monica Hoyos Flight Transthyretin (TTR) is a tetrameric protein that transports thyroxine and retinol in the blood; however, it is also amyloidogenic as it can form disease-causing aggregates. In the heart, aggregates of TTR lead to amyloid cardiomyopathy for which there is currently no approved therapy. A new (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387175 Fri, 14 Oct 2011 04:00:00 +0100 5387175 http://www.medworm.com/index.php?rid=5387172&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FFZy3HCh6slw%2Fnrd3587 Nature Reviews Drug Discovery 10, 814 (2011). doi:10.1038/nrd3587 Author: Sarah Crunkhorn Thiazolidinediones (TZDs), which are agonists of the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ), are effective at improving insulin sensitivity in patients with type 2 diabetes. However, major concerns have been raised in recent years about several adverse effects of TZDs. Now, writing in Nature, (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387172 Fri, 14 Oct 2011 04:00:00 +0100 5387172 http://www.medworm.com/index.php?rid=5387166&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FNgtIRVZYeYA%2Fnrd3594 Nature Reviews Drug Discovery 10, 802 (2011). doi:10.1038/nrd3594 Genentech has filed a new drug application with the US Food and Drug Administration for vismodegib, a Hedgehog (HH) pathway inhibitor that has shown promising results in a Phase II trial in patients with advanced basal cell carcinoma (BCC).The results of the trial, which (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387166 Fri, 14 Oct 2011 04:00:00 +0100 5387166 http://www.medworm.com/index.php?rid=5387165&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FE4RBIVgRMw0%2Fnrd3593 Nature Reviews Drug Discovery 10, 802 (2011). doi:10.1038/nrd3593 Results from a clinical trial of the novel oral anticoagulant apixaban in patients with atrial fibrillation showed that this factor Xa inhibitor was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding and resulted in a lower mortality rate (N. Engl. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5387165 Fri, 14 Oct 2011 04:00:00 +0100 5387165 http://www.medworm.com/index.php?rid=5274074&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F-MmgATPrKEg%2Fnrd3552 Authors: Paul D. Leeson & Stephen A. St-Gallay Physicochemical properties such as lipophilicity and molecular mass are known to have an important influence on the absorption, distribution, metabolism, excretion and toxicity (ADMET) profile of small-molecule drug candidates. To assess the use of this knowledge in reducing the likelihood of compound-related attrition, the molecular (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274074 Fri, 30 Sep 2011 04:00:00 +0100 5274074 http://www.medworm.com/index.php?rid=5274073&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FPO9TDTmoq6I%2Fnrd3550 Authors: Robert A. Beckman, Jason Clark & Cong Chen The future of drug development in oncology lies in identifying subsets of patients who will benefit from particular therapies, using predictive biomarkers. These technologies offer hope of enhancing the value of cancer medicines and reducing the size, cost and failure rates of clinical trials. However, (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274073 Fri, 30 Sep 2011 04:00:00 +0100 5274073 http://www.medworm.com/index.php?rid=5274072&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FA07Gu756dgE%2Fnrd3570 Nature Reviews Drug Discovery 10, 734 (2011). doi:10.1038/nrd3570 Protein–protein interactionsStructural conservation of druggable hot spots in protein–protein interfacesKozakov, D.et al. Proc. Natl Acad. Sci. USA1 Aug 2011 (doi: 10.1073/pnas.1101835108)Kozakov et al. used computational solvent mapping, which probes protein surfaces using small fragment molecules, (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274072 Fri, 30 Sep 2011 04:00:00 +0100 5274072 http://www.medworm.com/index.php?rid=5274071&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FRLZ_2RP22Lk%2Fnrd3566 Anticancer drugs: A sweet blow for cancer cells Nature Reviews Drug Discovery 10, 734 (2011). doi:10.1038/nrd3566 Author: Monica Hoyos Flight An emerging anticancer strategy known as synthetic lethal screening involves targeting tumour cells containing particular mutations with small molecules that are only cytotoxic to such cells and leave normal cells unharmed. In a study published in Science Translational Medicine, Chan and colleagues made use (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274071 Fri, 30 Sep 2011 04:00:00 +0100 5274071 http://www.medworm.com/index.php?rid=5274070&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FFW6hIbTYZJ4%2Fnrd3567 Antivirals: New clues for flu vaccine design Nature Reviews Drug Discovery 10, 733 (2011). doi:10.1038/nrd3567 Author: Sarah Crunkhorn Multiple subtypes and strains of influenza exist and new strains are constantly emerging. The development of vaccines providing long-term broad protection against influenza remains a key therapeutic goal. Now, a trio of studies have identified human antibodies exhibiting broadly neutralizing activity, which may have implications (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274070 Fri, 30 Sep 2011 04:00:00 +0100 5274070 http://www.medworm.com/index.php?rid=5274069&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FQd1Q1OJJF6s%2Fnrd3569 Anticancer drugs: Targeting MYC? You BET Nature Reviews Drug Discovery 10, 732 (2011). doi:10.1038/nrd3569 Author: Gemma K. Alderton Targeting the oncogenic effects of MYC could have wide application to treat cancer patients, but so far drug development has proved challenging. Bradner, Mitsiades and colleagues approached this problem by targeting MYC-mediated chromatin modifications.MYC target gene transactivation is associated with increased histone lysine acetylation, (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274069 Fri, 30 Sep 2011 04:00:00 +0100 5274069 http://www.medworm.com/index.php?rid=5274067&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FKZ1Gf2VN5RU%2Fnrd3568 Antivirals: Achilles heel of Ebola viral entry Nature Reviews Drug Discovery 10, 731 (2011). doi:10.1038/nrd3568 Author: Alexandra Flemming Ebola virus (EboV) infection causes fatal haemorrhagic fever with mortality rates exceeding 75%. Owing to the lack of available vaccines or therapeutics, it presents a considerable unmet medical need. Now, two studies in Nature identify a potential 'Achilles heel' of EboV and related filoviruses. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274067 Fri, 30 Sep 2011 04:00:00 +0100 5274067 http://www.medworm.com/index.php?rid=5274066&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FuJ_7JRKoqEw%2Fnrd3561 Authors: Carl E. Stafstrom, Seden Grippon & Peter Kirkpatrick Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274066 Fri, 30 Sep 2011 04:00:00 +0100 5274066 http://www.medworm.com/index.php?rid=5274065&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FfB1SBGmS8MM%2Fnrd3560 Authors: Ramanan Laxminarayan & John H. Powers Resistance to antibacterial drugs — an unavoidable consequence of their use — is a serious problem in many countries. Because the development of new antibacterials may have fallen behind the rate of antibacterial obsolescence, incentives for new drug development are needed. Recent reports have suggested (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274065 Fri, 30 Sep 2011 04:00:00 +0100 5274065 http://www.medworm.com/index.php?rid=5274064&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FR_MPWQTdR10%2Fnrd3575 Nature Reviews Drug Discovery 10, 726 (2011). doi:10.1038/nrd3575 In August the US Food and Drug Administration (FDA) simultaneously approved Roche and Plexikkon's BRAF inhibitor vemurafenib for metastatic melanoma and a companion diagnostic, the Cobas 4800 BRAF V600 mutation test. Shortly after, the agency gave the green light to Pfizer's ALK inhibitor crizotinib and a companion diagnostic for non-small cell lung cancer. These decisions, which marked the first co-development successes since the approval of trastuzumab for HER2-positive breast cancer in 1998, suggest that the era of companion diagnostics has arrived, at least in oncology. Yet Paul Brown, CEO of Roche Molecular Diagnostics, argues that the field still faces considerable uncertainties. Speaking with Asher Mullard, ... Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274064 Fri, 30 Sep 2011 04:00:00 +0100 5274064 http://www.medworm.com/index.php?rid=5274063&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FxmNKpmXTDlE%2Fnrd3574 Nature Reviews Drug Discovery 10, 724 (2011). doi:10.1038/nrd3574 Court considers immunization methodsThe US Court of Appeals for the Federal Circuit (CAFC) has held that two patents claiming methods to determine whether an immunization schedule affects the incidence or severity of a chronic immune-mediated disorder meet certain conditions necessary for patentability. The decision (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274063 Fri, 30 Sep 2011 04:00:00 +0100 5274063 http://www.medworm.com/index.php?rid=5274062&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FIc1OiLmcJP4%2Fnrd3564 Market watch: Upcoming market catalysts in Q4 2011 Nature Reviews Drug Discovery 10, 723 (2011). doi:10.1038/nrd3564 Author: John Tucker Key market catalysts in the fourth quarter of 2011 include top-line results from a Phase III trial of alemtuzumab in relapsing–remitting multiple sclerosis (RRMS), and decisions by the US Food and Drug Administration (FDA) on the approval of dapagliflozin for the treatment of type 2 (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274062 Fri, 30 Sep 2011 04:00:00 +0100 5274062 http://www.medworm.com/index.php?rid=5274061&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FqjZV1dxNv_U%2Fnrd3563 Trial watch: First-in-human studies with cardiac myosin activators Nature Reviews Drug Discovery 10, 722 (2011). doi:10.1038/nrd3563 The first in a new potential class of drugs to treat heart failure — cardiac myosin activators — has shown encouraging results in a Phase I trial and a small Phase II trial. Omecamtiv mecarbil, developed by Cytokinetics and licensed to Amgen, targets myosin — (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274061 Fri, 30 Sep 2011 04:00:00 +0100 5274061 http://www.medworm.com/index.php?rid=5274060&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FpbpeYScY8fo%2Fnrd3562 Trial watch: IL-13 antibody improves lung function in asthma Nature Reviews Drug Discovery 10, 722 (2011). doi:10.1038/nrd3562 Results from a Phase II clinical trial of lebrikizumab (N. Engl. J. Med. 3 Aug 2011; doi:10.1056/NEJMoa1106469), a humanized monoclonal antibody that targets interleukin-13 (IL-13), have shown that the biologic improves lung function in adults with uncontrolled asthma.Girolamo Pelaia, (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274060 Fri, 30 Sep 2011 04:00:00 +0100 5274060 http://www.medworm.com/index.php?rid=5274059&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FE-hsoCTGVhY%2Fnrd3573 Nature Reviews Drug Discovery 10, 721 (2011). doi:10.1038/nrd3573 First priority review voucher wastedNovartis redeemed its priority review voucher earlier this year to secure a speedy assessment of canakinumab in gouty arthritis, but the FDA nevertheless recently ruled against approval.The lowdown: In 2007, the US government created priority review vouchers to (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274059 Fri, 30 Sep 2011 04:00:00 +0100 5274059 http://www.medworm.com/index.php?rid=5274058&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F-iiAYSWksxI%2Fnrd3572 Nature Reviews Drug Discovery 10, 719 (2011). doi:10.1038/nrd3572 Author: Asher Mullard Over a decade since gene therapy development came to a near standstill with the death of a clinical trial participant, the field is overcoming issues of immunogenicity, carcinogenicity, manufacturing and small patient populations. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274058 Fri, 30 Sep 2011 04:00:00 +0100 5274058 http://www.medworm.com/index.php?rid=5274057&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FrcPatYf2CAs%2Fnrd3571 Nature Reviews Drug Discovery 10, 717 (2011). doi:10.1038/nrd3571 Author: Elie Dolgin Drugs that block Janus kinases are showing promise in diseases ranging from myelofibrosis to rheumatoid arthritis, but with the leading agent in line for approval questions remain about their optimal selectivity. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274057 Fri, 30 Sep 2011 04:00:00 +0100 5274057 http://www.medworm.com/index.php?rid=5274056&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FzXoTyWpgLoc%2Fnrd3559 Nature Reviews Drug Discovery 10, 715 (2011). doi:10.1038/nrd3559 Author: Darryle D. Schoepp The challenges of developing drugs for central nervous system disorders have led some major companies to reduce or discontinue investment in the field, even though the unmet medical need is substantial. How can the wealth of basic research knowledge in neuroscience be successfully translated into (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274056 Fri, 30 Sep 2011 04:00:00 +0100 5274056 http://www.medworm.com/index.php?rid=5274055&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FVNc5O3sdzXc%2Fnrd3558 Nature Reviews Drug Discovery 10, 713 (2011). doi:10.1038/nrd3558 Our understanding of the influence of physicochemical properties of drug candidates on their pharmacokinetic and toxicity profiles has improved substantially in the past 15 years. To investigate the impact of this knowledge, Leeson and St-Gallay analyse the properties of compounds described in patents from 18 (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274055 Fri, 30 Sep 2011 04:00:00 +0100 5274055 http://www.medworm.com/index.php?rid=5274076&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F3e4eohBli00%2Fnrd3551 Authors: Stefan Nilsson, Konrad F. Koehler & Jan-Åke Gustafsson The two oestrogen receptor subtypes α and β are hormone-regulated modulators of intracellular signalling and gene expression. Regulation of oestrogen receptor activity is crucial not only for development and homeostasis but also for the treatment of various diseases and symptoms. Classical selective oestrogen receptor modulators (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274076 Fri, 16 Sep 2011 04:00:00 +0100 5274076 http://www.medworm.com/index.php?rid=5274075&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FxoWf7Ck1n0Q%2Fnrd3554 Authors: Dario Neri & Claudiu T. Supuran The high metabolic rate of tumours often leads to acidosis and hypoxia in poorly perfused regions. Tumour cells have thus evolved the ability to function in a more acidic environment than normal cells. Key pH regulators in tumour cells include: isoforms 2, 9 and 12 (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274075 Fri, 16 Sep 2011 04:00:00 +0100 5274075 http://www.medworm.com/index.php?rid=5274068&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FQTBJqbp3E78%2Fnrd3565 Nature Reviews Drug Discovery 10, 732 (2011). doi:10.1038/nrd3565 Author: Charlotte Harrison Identifying new therapeutic uses for approved drugs — known as drug repositioning — can reduce development costs and accelerate regulatory approval. Two papers by Butte and colleagues in Science Translational Medicine used computational analysis of publicly available gene expression data to suggest potential new (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5274068 Fri, 16 Sep 2011 04:00:00 +0100 5274068 http://www.medworm.com/index.php?rid=5184204&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FCh2Z71Qed8M%2Fnrd3439-c1 Authors: Florian Prinz, Thomas Schlange & Khusru Asadullah A recent report by Arrowsmith noted that the success rates for new development projects in Phase II trials have fallen from 28% to 18% in recent years, with insufficient efficacy being the most frequent reason for failure (Phase II failures: 2008–2010. Nature Rev. Drug Discov. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184204 Tue, 30 Aug 2011 23:00:00 +0100 5184204 http://www.medworm.com/index.php?rid=5184201&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FzdfmDAEg4r0%2Fnrd3504 Nature Reviews Drug Discovery 10, 671 (2011). doi:10.1038/nrd3504 Author: Matthew G. Vander Heiden Genetic events in cancer activate signalling pathways that alter cell metabolism. Clinical evidence has linked cell metabolism with cancer outcomes. Together, these observations have raised interest in targeting metabolic enzymes for cancer therapy, but they have also raised concerns that these therapies would have unacceptable (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184201 Tue, 30 Aug 2011 23:00:00 +0100 5184201 http://www.medworm.com/index.php?rid=5184200&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FyHCJYsI_GaQ%2Fnrd3503 Authors: Sandra Orchard, Bissan Al-Lazikani, Steve Bryant, Dominic Clark, Elizabeth Calder, Ian Dix, Ola Engkvist, Mark Forster, Anna Gaulton, Michael Gilson, Robert Glen, Martin Grigorov, Kim Hammond-Kosack, Lee Harland, Andrew Hopkins, Christopher Larminie, Nick Lynch, Romeena K. Mann, Peter Murray-Rust, Elena Lo Piparo, Christopher Southan, Christoph Steinbeck, David Wishart, Henning Hermjakob, John Overington & Janet Thornton Bioactive molecules such as drugs, pesticides and food additives are produced in large numbers by many commercial and academic groups around the world. Enormous quantities of data are generated on the biological properties and quality of these molecules. Access to such data — both on (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184200 Tue, 30 Aug 2011 23:00:00 +0100 5184200 http://www.medworm.com/index.php?rid=5184199&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FAtJ6weEs3LY%2Fnrd3544 Nature Reviews Drug Discovery 10, 660 (2011). doi:10.1038/nrd3544 G protein-coupled receptorsCrystal structure of the β2 adrenergic receptor–Gs protein complexRasmussen, S. G. F.et al. Nature19 Jul 2011 (doi:10.1038/nature10361)Agonist binding to G protein-coupled receptors (GPCRs) leads to the activation of G proteins and (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184199 Tue, 30 Aug 2011 23:00:00 +0100 5184199 http://www.medworm.com/index.php?rid=5184198&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FrGkIeirw6lw%2Fnrd3541 Cognitive impairment: Rescuing age-related memory loss Nature Reviews Drug Discovery 10, 660 (2011). doi:10.1038/nrd3541 Author: Monica Hoyos Flight Forgetfulness, distractibility and impaired executive function are manifestations of the normal ageing process in both humans and monkeys, and can be observed as early as in middle age. This decline in working memory is associated with prefrontal cortex (PFC) dysfunction, but the underlying molecular basis (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184198 Tue, 30 Aug 2011 23:00:00 +0100 5184198 http://www.medworm.com/index.php?rid=5184197&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F2pvnIuaP2nw%2Fnrd3540 Metabolic disease: Turning 'bad' fat into 'good' Nature Reviews Drug Discovery 10, 659 (2011). doi:10.1038/nrd3540 Author: Sarah Crunkhorn Excess calories are stored as fat in white adipose tissue (WAT), which — over time — leads to the development of obesity and associated metabolic diseases. Although most current obesity therapies aim to reduce caloric intake, accumulating evidence suggests that increasing cellular energy expenditure may (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184197 Tue, 30 Aug 2011 23:00:00 +0100 5184197 http://www.medworm.com/index.php?rid=5184196&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FYndFtTYKJkQ%2Fnrd3543 Anticancer Drugs: Selective oxycution? Nature Reviews Drug Discovery 10, 658 (2011). doi:10.1038/nrd3543 Author: Darren J. Burgess One of the greatest challenges that is still to be widely addressed by anticancer therapies is the selective killing of cancer cells on the basis of cancer-specific features, rather than on generic properties that are shared with normal cells. New research shows that a natural (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184196 Tue, 30 Aug 2011 23:00:00 +0100 5184196 http://www.medworm.com/index.php?rid=5184195&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FpWYq40J6xg8%2Fnrd3539 Vaccines: Structure-based design Nature Reviews Drug Discovery 10, 658 (2011). doi:10.1038/nrd3539 Author: Charlotte Harrison The development of vaccines against pathogens such as meningococcus B, rhinovirus, African trypanosomes and HIV has been hampered owing to the high degree of sequence variability of their respective antigens. Writing in Science Translational Medicine, Rappuoli and colleagues used a structure-based vaccine design to (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184195 Tue, 30 Aug 2011 23:00:00 +0100 5184195 http://www.medworm.com/index.php?rid=5184194&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FZwTgpajVSeA%2Fnrd3542 Diabetes: Mobilizing regulatory T cells against type 1 diabetes Nature Reviews Drug Discovery 10, 657 (2011). doi:10.1038/nrd3542 Author: Alexandra Flemming Type 1 diabetes (TD1) is characterized by the autoimmune destruction of pancreatic β-cells. Several immuno-therapeutic approaches are being investigated that aim to prevent the onset of disease in individuals 'at risk', including vaccination strategies with natural insulin epitopes. However, results from clinical trials have so (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184194 Tue, 30 Aug 2011 23:00:00 +0100 5184194 http://www.medworm.com/index.php?rid=5184193&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FkKeWMiaOxko%2Fnrd3536 Authors: Flavio Vincenti, Argyris Dritselis & Peter Kirkpatrick In June 2011, belatacept (Nulojix; Bristol-Myers Squibb), a fusion protein that inhibits T cell activation by binding to CD80 and CD86, was approved by the US Food and Drug Administration (FDA) for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184193 Tue, 30 Aug 2011 23:00:00 +0100 5184193 http://www.medworm.com/index.php?rid=5184192&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FT5FalIPCTUQ%2Fnrd3555 Authors: Peter Tollman, Yves Morieux, Jeanine Kelly Murphy & Ulrik Schulze Research and development (R&D) is the ultimate source of the economic value that the pharmaceutical industry creates. It is therefore not surprising that the evidence of a major decline in R&D productivity has led to a sense of crisis. Indeed, from 2000 to 2010 the (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184192 Tue, 30 Aug 2011 23:00:00 +0100 5184192 http://www.medworm.com/index.php?rid=5184191&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FxoREKjZPM7c%2Fnrd3549 Nature Reviews Drug Discovery 10, 652 (2011). doi:10.1038/nrd3549 As part of the Affordable Care Act of 2010, the US Congress created the Patient-Centered Outcomes Research Institute (PCORI). Just over a year since the creation of the comparative effectiveness research (CER) organization, the PCORI has now appointed its first Executive Director, Joe Selby. A physician who formerly directed research at Kaiser Permanente, northern California, Selby will now supervise the formation of the nascent institute's plan of action. And by 2014 he will be overseeing an expected annual research budget of US$500 million. Speaking with Asher Mullard, Selby explained the case and agenda for the PCORI. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184191 Tue, 30 Aug 2011 23:00:00 +0100 5184191 http://www.medworm.com/index.php?rid=5184190&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FQqZN1duC3jQ%2Fnrd3548 Nature Reviews Drug Discovery 10, 650 (2011). doi:10.1038/nrd3548 DNA patent decision leaves questions for diagnosticsThe US Court of Appeals for the Federal Circuit (CAFC) has held that isolated DNA molecules are patentable, because in their opinion such molecules do not exist in nature. Although the decision is likely to be welcomed by (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184190 Tue, 30 Aug 2011 23:00:00 +0100 5184190 http://www.medworm.com/index.php?rid=5184189&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F5M06KpJ4M14%2Fnrd3538 Trial watch: ERBB2 dimerization inhibitor meets end point in breast cancer trial Nature Reviews Drug Discovery 10, 648 (2011). doi:10.1038/nrd3538 Preliminary results from a Phase III clinical trial of pertuzumab, an antibody that prevents dimerization of the ERBB2 (also known as HER2) receptor with other ligand-activated ERBB receptors, have shown that the drug significantly extended the progression-free survival of patients with ERBB2-positive metastatic breast cancer. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184189 Tue, 30 Aug 2011 23:00:00 +0100 5184189 http://www.medworm.com/index.php?rid=5184188&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FBlmt2_SOSpc%2Fnrd3537 Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system Nature Reviews Drug Discovery 10, 648 (2011). doi:10.1038/nrd3537 Bristol-Myers Squibb has acquired exclusive global rights to Innate Pharma's cancer candidate IPH 2102, which is in Phase I clinical trials for acute myeloid leukaemia (AML). Innate Pharma will receive US$35 million upfront and is eligible to receive up to $430 million in milestones.IPH (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184188 Tue, 30 Aug 2011 23:00:00 +0100 5184188 http://www.medworm.com/index.php?rid=5184187&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FIXGKxwg5Yis%2Fnrd3547 Nature Reviews Drug Discovery 10, 647 (2011). doi:10.1038/nrd3547 Gene-editing TALENs make the cutThree papers in Nature Biotechnology demonstrate the potential of TALENs as emerging gene-editing tools.The lowdown: Transcription activator-like effector nucleases (TALENs) have steadily been gaining attention as gene-editing tools in part because of their apparently simple sequence-specific DNA (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184187 Tue, 30 Aug 2011 23:00:00 +0100 5184187 http://www.medworm.com/index.php?rid=5184186&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F2MyAeHlCzqI%2Fnrd3546 Nature Reviews Drug Discovery 10, 645 (2011). doi:10.1038/nrd3546 Author: Dan Jones Concerns about cancer risks prompted a negative vote by an FDA advisory committee on the SGLT2 inhibitor dapagliflozin, but experts remain hopeful for the novel class of antidiabetic drugs. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184186 Tue, 30 Aug 2011 23:00:00 +0100 5184186 http://www.medworm.com/index.php?rid=5184185&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fca7xHYXPbVE%2Fnrd3545 Nature Reviews Drug Discovery 10, 643 (2011). doi:10.1038/nrd3545 Author: Asher Mullard Bayer halts nearly two-thirds of its target-validation projects because in-house experimental findings fail to match up with published literature claims, finds a first-of-a-kind analysis on data irreproducibility. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184185 Tue, 30 Aug 2011 23:00:00 +0100 5184185 http://www.medworm.com/index.php?rid=5184184&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F88Vb74gCbQc%2Fnrd3534 Authors: Ismail Kola & John Bell A coordinated effort to incorporate advances in the understanding of the molecular and genomic variations in common diseases, such as hypertension, into their diagnosis and treatment could transform drug development and medicine. (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184184 Tue, 30 Aug 2011 23:00:00 +0100 5184184 http://www.medworm.com/index.php?rid=5184183&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FnxCvrTkYioU%2Fnrd3533 Nature Reviews Drug Discovery 10, 639 (2011). doi:10.1038/nrd3533 Tumour metabolism is currently one of the most intense areas of cancer research. Although it has long been recognized that the metabolism of cancer cells differs from that of normal cells, opportunities to therapeutically exploit these differences have only recently emerged. In our first Review, (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184183 Tue, 30 Aug 2011 23:00:00 +0100 5184183 http://www.medworm.com/index.php?rid=5184203&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FXxhs8Bz663Q%2Fnrd3505 Authors: Eric Karran, Marc Mercken & Bart De Strooper The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5184203 Thu, 18 Aug 2011 23:00:00 +0100 5184203 http://www.medworm.com/index.php?rid=5079672&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F4X8yCNYahGg%2Fnrd3459 Authors: Francesco Muntoni & Matthew J. A. Wood The development of effective therapies for neuromuscular disorders such as Duchenne muscular dystrophy (DMD) is hampered by considerable challenges: skeletal muscle is the most abundant tissue in the body, and many neuromuscular disorders are multisystemic conditions. However, despite these barriers there has recently been substantial (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079672 Sun, 31 Jul 2011 23:00:00 +0100 5079672 http://www.medworm.com/index.php?rid=5079671&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FlVUwQE_ndLk%2Fnrd3456 Authors: Magdalene M. Moran, Michael Allen McAlexander, Tamás Bíró & Arpad Szallasi Transient receptor potential (TRP) cation channels have been among the most aggressively pursued drug targets over the past few years. Although the initial focus of research was on TRP channels that are expressed by nociceptors, there has been an upsurge in the amount of research (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079671 Sun, 31 Jul 2011 23:00:00 +0100 5079671 http://www.medworm.com/index.php?rid=5079670&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FxhzyBtQIyaU%2Fnrd3500 Authors: W. Joost Lesterhuis, John B. A. G. Haanen & Cornelis J. A. Punt Our insight into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors. These include difficulties in the selection of the optimal dose and schedule, the methods of (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079670 Sun, 31 Jul 2011 23:00:00 +0100 5079670 http://www.medworm.com/index.php?rid=5079669&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FoOCyjH1Y4H0%2Fnrd3478 Authors: Mathias Rask-Andersen, Markus Sällman Almén & Helgi B. Schiöth The discovery and exploitation of new drug targets is a key focus for both the pharmaceutical industry and academic biomedical research. To provide an insight into trends in the exploitation of new drug targets, we have analysed the drugs that were approved by the US (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079669 Sun, 31 Jul 2011 23:00:00 +0100 5079669 http://www.medworm.com/index.php?rid=5079668&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FXxB-0jf9DWM%2Fnrd3523 Nature Reviews Drug Discovery 10, 578 (2011). doi:10.1038/nrd3523 Author: Charlotte Harrison Current therapies for deep vein thrombosis (DVT) — which can occur as a result of immobilization, surgery and pregnancy — such as heparins, warfarin and the new-generation anticoagulants act on the coagulation cascade rather than directly targeting the thrombus. Now, Nosaka and colleagues show that (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079668 Sun, 31 Jul 2011 23:00:00 +0100 5079668 http://www.medworm.com/index.php?rid=5079667&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2F3gUddheNEnY%2Fnrd3520 Nature Reviews Drug Discovery 10, 577 (2011). doi:10.1038/nrd3520 Author: Monica Hoyos Flight Ketamine, an injectable drug that is used to induce anaesthesia in surgery, also has a rapid and sustained antidepressant effect. However, its psychotomimetic and cognitive effects preclude its long-term use. As currently available antidepressants commonly take weeks to reach efficacy, understanding the fast mechanism of (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079667 Sun, 31 Jul 2011 23:00:00 +0100 5079667 http://www.medworm.com/index.php?rid=5079666&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fywp1xcw0tng%2Fnrd3522 Obesity and diabetes: Lipid boosts muscle and shrinks fat Nature Reviews Drug Discovery 10, 576 (2011). doi:10.1038/nrd3522 Author: Samia Burridge Atrophy — the loss of muscle — is a common problem in ageing and in many diseases. As there is currently no therapy, a compound that is able to reduce atrophy could potentially become a useful drug. Now, Adams and colleagues have identified ursolic acid (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079666 Sun, 31 Jul 2011 23:00:00 +0100 5079666 http://www.medworm.com/index.php?rid=5079665&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2FKU5g5QNaiLM%2Fnrd3521 Nature Reviews Drug Discovery 10, 576 (2011). doi:10.1038/nrd3521 Author: Sarah Crunkhorn The precise pathophysiological mechanisms underlying neuro-degenerative disorders such as Alzheimer's disease (AD) and Huntington's disease (HD) remain unclear, and no disease-modifying therapies currently exist. Now, two papers show that manipulating the kynurenine pathway (KP) of tryptophan degradation can ameliorate neurodegeneration in animal models of disease, (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079665 Sun, 31 Jul 2011 23:00:00 +0100 5079665 http://www.medworm.com/index.php?rid=5079664&cid=s_32561_13_f&fid=32561&url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnrd%2Frss%2Fcurrent%2F%7E3%2Fro4atuoJ97k%2Fnrd3524 Nature Reviews Drug Discovery 10, 575 (2011). doi:10.1038/nrd3524 Author: Alexandra Flemming Immunotherapeutic and virus-based anticancer strategies have attracted increasing interest in recent years, and oncolytic virus-based vaccine therapies have reached late-stage clinical trials. Now, reporting in Nature Medicine, the group of Richard Vile present a virus-based anticancer strategy that works predominantly by an immune-enhancing rather (Source: Nature Reviews Drug Discovery) Nature Reviews Drug Discovery journals http://www.medworm.com/rss/comments.php?id=5079664 Sun, 31 Jul 2011 23:00:00 +0100 5079664